$PCYC Headlines Mid-caps rattle cage on all-time highs

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 12:45 PM

$PCYC Headlines

Mid-caps rattle cage on all-time highs 10:58 a.m. Nov. 13, 2014 - Michael Ashbaugh
Market technicals bend, but don’t break 9:21 a.m. Sept. 11, 2014 - Michael Ashbaugh
Charting the U.S. markets’ next technical tests 10:32 a.m. Aug. 4, 2014 - Michael Ashbaugh
5 stocks to watch 12:50 p.m. July 30, 2014 - The Trading Deck
Biotech hammered as ETFs down 5%, while some stocks fall 10% 12:55 p.m. April 10, 2014 - Russ Britt
Is biotech caught in a bubble, and is it popping? 12:13 p.m. April 8, 2014 - Russ Britt
S&P 500’s slow-motion breakout attempt ‘rages on’ 11:43 a.m. Feb. 27, 2014 - Michael Ashbaugh
FDA approval of leukemia treatment boosts shares of Pharmacyclics 1:57 p.m. Feb. 12, 2014 - Russ Britt
Pharmacyclics shares soar after panel says cancer drug met goals 12:09 p.m. Jan. 7, 2014 - Russ Britt
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Health care leads S&P as St. Jude gets some good news from FDA 10:49 a.m. Oct. 4, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Pharmacyclics shares jump after FDA accepts new cancer drug filing 11:09 a.m. Aug. 29, 2013 - Russ Britt
S&P 500 ventures to uncharted territory 11:21 a.m. July 18, 2013 - Michael Ashbaugh
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
Positives continue to build for the Nasdaq 12:31 p.m. June 4, 2013 - The Trading Deck
For the medium-term trader, setups galore 10:39 a.m. May 14, 2013 - The Trading Deck
After the close: Big gains for Pharmacyclics, Biogen, Warner 4:39 p.m. May 13, 2013 - Russ Britt
FDA gives 'breakthrough' designation to Merck drug 8:10 p.m. April 23, 2013 - MarketWatch.com

Imbruvica performs well in high-risk leukemia patients 12:15 p.m. Jan. 5, 2015 - Seeking Alpha
IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 8:02 a.m. Jan. 5, 2015 - benzinga.com
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility 10:45 a.m. Jan. 2, 2015 - Seeking Alpha
Bull of the Day: Incyte (INCY) - Bull of the Day 1:00 a.m. Jan. 2, 2015 - Zacks.com
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog 4:15 p.m. Dec. 31, 2014 - Zacks.com
DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially 7:05 a.m. Dec. 30, 2014 - Seeking Alpha
13 Biotechnology Stocks to Buy Now 3:45 a.m. Dec. 24, 2014 - InvestorPlace.com
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Pharmacyclics (PCYC) Is Water-Logged And Getting Wetter Today 12:10 p.m. Dec. 23, 2014 - TheStreet.com
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day 1:00 a.m. Dec. 19, 2014 - Zacks.com
11 Biotechnology Stocks to Buy Now 3:15 a.m. Dec. 17, 2014 - InvestorPlace.com
Nasdaq makes annual changes to Biotechnology Index 12:36 p.m. Dec. 15, 2014 - Seeking Alpha
11 Very Popular Stocks Now Valued Over 50 Times Earnings 7:11 a.m. Dec. 10, 2014 - 247WallSt.com
9 Biotechnology Stocks to Buy Now 4:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma 8:02 a.m. Dec. 9, 2014 - benzinga.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the Tape 8:35 a.m. Dec. 4, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:41 a.m. Dec. 3, 2014 - Zacks.com
10 Biotechnology Stocks to Buy Now 4:15 a.m. Dec. 3, 2014 - InvestorPlace.com

Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 1:43 p.m. Dec. 8, 2014 - GlobeNewswire
Critical Alerts For Nuverra Environmental Solutions, Marvell Technology, Pharmacyclics, Aeropostale and Rockwell Medical Released By InvestorsObserver 9:31 a.m. Nov. 21, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Keith Lui Joins Versartis to Lead Global Marketing Efforts 8:32 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 7:40 a.m. Oct. 30, 2014 - PR Newswire - PRF
Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results 5:11 p.m. Oct. 28, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 8:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia 7:05 a.m. Oct. 20, 2014 - PR Newswire - PRF
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers 7:49 a.m. Oct. 17, 2014 - PR Newswire - PRF
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma 7:45 a.m. Sept. 26, 2014 - PR Newswire - PRF
Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration 3:01 p.m. Sept. 25, 2014 - PR Newswire - PRF
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 8:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
Financing Strategies, Financing Packages, Recognitions, Technical Updates, and Appointments - Research Reports on Aon, U.S. Bancorp, Ally Financial, Teva and Pharmacyclics 8:10 a.m. Aug. 22, 2014 - PR Newswire - PRF
Pharmacyclics Appoints Chief Commercial Officer 3:05 p.m. Aug. 18, 2014 - PR Newswire - PRF
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc. 8:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 7:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Pharmacyclics Reports Second Quarter 2014 Results 3:04 p.m. July 31, 2014 - PR Newswire - PRF
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver 8:31 a.m. July 30, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Merit Advisors Shines as Top Energy Workplace

Well, here's something to chew on—Merit Advisors just grabbed the top spot on Hart Energy's first-ever Best Places to Work in Energy list. If you haven't heard of them, Merit's the heavyweight champ in specialty tax for the energy sector. This isn't just a shiny trophy on the shelf; it's a nod to the kind of culture that's making waves in an industry that's no stranger...

Atli Launches: AI-Powered eSIM Revolutionizes Travel

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Veho's Role in Redefining Beauty E-Commerce Delivery

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...

AI Trust in Finance: Survey Reveals Market Impact

Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....

Cove Capital Secures $9.96M for Debt-Free Logistics DST

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Deadline Looms for EquipmentShare Investors' Legal Action

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Helio Fred Garcia Honored by Diversity Action Alliance

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...